ARQT
NASDAQArcutis Biotherapeutics Inc.
Price$28.84+1.11 (+4.02%)
2026-07-162026-10-16
News · 26 weeks73-17%
2026-04-262026-10-18
Mix3090d
- Insider11(37%)
- Other9(30%)
- SEC Filings7(23%)
- Earnings1(3%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- ANALYSTCantor Fitzgerald initiated coverage on Arcutis Biotherapeutics with a new price targetCantor Fitzgerald initiated coverage of Arcutis Biotherapeutics with a rating of Overweight and set a new price target of $48.00
- PRArcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalPresentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limitedNew analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasisAdditional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitisReal-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeut
- PRArcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty AwardNewly created award category highlights innovation in prescription skin treatmentZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the awardZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with th
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listin
- PRSimone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment OptionsSimone Biles opens up about her experience managing the symptoms of these conditions and encourages long-term control of skin healthBiles’ treatment, ZORYVE® (roflumilast), is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined — seborrheic dermatitis, eczema, and plaque psoriasis WESTLAKE VILLAGE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that World Champion gymnast Simone Biles has partnered with the company to launch its Skin to Believe In awareness campaign. The campai
- INSIDEROfficer Matsuda Masaru sold $91,853 worth of shares (3,674 units at $25.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,508 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $114,371 worth of shares (4,730 units at $24.18) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 35,841 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Matsuda Masaru sold $249,986 worth of shares (9,989 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 116,182 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- PRBloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector Sept 21, 2026 S&P 100AdditionDell Techno
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 57,000 restricted stock units (RSUs) of Arcutis common stock to 11 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq List
- PRArcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceWESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026, in New York. Details for the Company’s participation are as follows: Fireside Chat: Wednesday, September 16, 2026, at 1:50 p.m. ET The webcast for this conference may be accessed via the "Events" section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the c
- INSIDERDirector Curran Terrie sold $956,123 worth of shares (38,200 units at $25.03) and exercised 38,200 shares at a strike of $8.30 (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDERDirector Curran Terrie sold $27,912 worth of shares (1,072 units at $26.04) and exercised 1,072 shares at a strike of $7.51 (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Burnett Patrick sold $45,819 worth of shares (1,697 units at $27.00), decreasing direct ownership by 1% to 117,592 units (SEC Form 4) (tax withholding)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRPrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic DermatitisHealth Canada approval of new 0.05% cream formulation expands the ZORYVE portfolio to include a once-daily, steroid-free option for younger childrenThe 0.05% formulation was specifically selected for young children, with clinical studies demonstrating significant improvements in disease severity as early as Week 1Long-term extension study demonstrated a consistent safety profile through 56 weeksTORONTO, Aug. 20, 2026 /CNW/ -- Arcutis Canada, Inc., a commercial stage company focused on delivering meaningful innovations in immuno-dermatology, today announced that Health Canada has approved PrZORYVE® (roflumilast) cream 0.05% for the topical treatment of mild to moderate atopic dermatitis (AD)
- INSIDERDirector Welgus Howard G. exercised 4,096 shares at a strike of $7.93 and sold $123,835 worth of shares (4,730 units at $26.18) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 36,475 units (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDEROfficer Burnett Patrick exercised 15,000 shares at a strike of $3.64 and sold $394,897 worth of shares (15,000 units at $26.33) (SEC Form 4)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- SECSEC Form 144 filed by Arcutis Biotherapeutics Inc.144 - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- PRArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis’ common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis’ common stock to 24 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 3, 2026, as a material inducement to the new employees in connectio
- SECSEC Form SCHEDULE 13G filed by Arcutis Biotherapeutics Inc.SCHEDULE 13G - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)
- INSIDEROfficer Burnett Patrick sold $24,942 worth of shares (955 units at $26.12), decreasing direct ownership by 0.79% to 119,289 units (SEC Form 4) to satisfy withholding tax4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
- INSIDEROfficer Matsuda Masaru sold $32,124 worth of shares (1,230 units at $26.12), decreasing direct ownership by 0.97% to 126,171 units (SEC Form 4) (withholding tax)4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)
ARQT FAQ
7 questionsWhat does Arcutis Biotherapeutics Inc. do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252...Where does ARQT stock trade?
Arcutis Biotherapeutics Inc. (ARQT) is listed on NASDAQ.What sector and industry is ARQT in?
Arcutis Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arcutis Biotherapeutics Inc. go public?
Arcutis Biotherapeutics Inc. (ARQT) completed its IPO in 2020.What are analysts saying about ARQT?
Arcutis Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $4800.00 price target on 2026-10-15.What companies are similar to ARQT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARQT side-by-side with any of them on Quantisnow.How can I track ARQT on Quantisnow?
Quantisnow aggregates Arcutis Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARQT to receive live email and push alerts on every new disclosure.